BioSpace News Archive

Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) (“Allena” or the “Company”), a late-stage biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to-treat metabolic diseases, today reported financial results for the second quarter ended June 30, 2021 and highlighted recent corporate progress.

New research has revealed a significant reduction in the need for total hip and knee replacement surgery among rheumatoid arthritis patients after the introduction of biologics.

BioCryst Pharmaceuticals, Inc. announced that it has withdrawn its proposed public offering.

Mirum Pharmaceuticals, Inc. announced that on August 10, 2021, the Compensation Committee of Mirum’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 95,200 shares of common stock to eight new employees under Mirum’s 2020 Inducement Plan.

ImmVira announced that it has initiated its lead oncolytic virus therapy program MVR-T3011 IV (also known as T3011). The first patient has been dosed, receiving MVR-T3011 intravenous (IV) administration in the U.S. on August 10, 2021.

Rakuten Medical, Inc. today announced that it has appointed Nitin Nohria and Hiroshi Takasawa to the company’s board of directors.

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company developing niche generic products, announced that the first quarter financial results of the 2022 fiscal year will be released on Monday, August 16, 2021.

QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) and GT Molecular, a leader in providing customizable, highly sensitive digital PCR and qPCR tests based in the U.S., have started to offer a complete wastewater workflow solution designed to enable surveillance of COVID-19 outbreaks by U.S. and Canadian laboratories, with future options to offer the solution in other countries.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced its participation in one-on-one investor meetings as well as a virtual panel discussion at the 12th Annual Wedbush PacGrow Healthcare Conference.

RxSight, Inc., an ophthalmic medical device company, announced the appointment of three new members to its Board of Directors effective as of the closing of the Company’s initial public offering on August 3, 2021.